Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors-Reference-Cited by-同舟云学术

Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors

Published:2023-07-21 Issue:14 Volume:15 Page:3712
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Varghese Diana Grace¹,Del Rivero Jaydira¹^ORCID,Bergsland Emily²^ORCID

Affiliation:

1. Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 94158, USA

2. UCSF Helen Diller Family Comprehensive Cancer Center and Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94158, USA

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (NENs) are a heterogenous group of tumors that are incurable when metastatic, regardless of grade. The aim of this article is to understand tumor heterogeneity and grade progression as possible contributors to drug resistance in gastroentropancreatic neuroendocrine tumors (GEP-NETs). Heterogeneity has been observed in the genetic, pathological, and imaging features of these tumors at baseline. Diagnostic challenges related to tumor sampling and the potential for changes in grade over time further confound our ability to optimize therapy for patients. A better understanding of NEN biology and tumor heterogeneity at baseline and over time could lead to the development of new therapeutic avenues.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/14/3712/pdf

Reference95 articles.

1. Lloyd, R.V., Osamura, R.Y., Klöppel, G., and Rosai, J. (2017). WHO Classification of Tumours of Endocrine Organs, International Agency for Research on Cancer. [4th ed.].

2. WHO (2019). WHO Classification of Digestive System Tumours, IARC. [5th ed.].

3. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms;Rindi;Endocr. Pathol.,2022

4. WHO Classification of Tumours Editorial Board (2022). WHO Classification of Endocrine and Neuroendocrine Tumours, IARC.

5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE);Capdevila;Oncologist,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression;memo - Magazine of European Medical Oncology;2024-04-29

2. Follow-up study of a Colombian family with a novel MEN1 variant and rare ACTH-producing pancreatic neuroendocrine carcinoma;2023-12-08